# About Pharmacy Wolverine: An Editorial BPC-157 TB-500 Digest

> About Pharmacy Wolverine — an independent editorial project that digests the peer-reviewed BPC-157 TB-500 literature. Not a clinic, not a pharmacy, not a vendor.

An independent editorial project that reads the published literature on the Wolverine blend, one constituent at a time, and keeps the access status in plain sight.

## What Pharmacy Wolverine is

Pharmacy Wolverine is an independent editorial project that publishes summaries of the peer-reviewed research literature on the BPC-157 TB-500 "Wolverine" blend. We are not a clinic. We do not employ clinicians, and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The "pharmacy" in the name is editorial framing — a position this publisher occupies relative to the literature and the access question, not a claim about services. There is no pharmacy here, no counter, no dispensing, and nothing for sale. What there is: a careful, cited reading of what the studies on each peptide actually establish, and a present-tense, FDA-sourced account of where compounding access stands.

## Why a street wall

"Wolverine" is itself a street name — a research-community and gym-forum tag for the BPC-157 + TB-500 pairing, conflated with the X-Men character, marketed in athlete forums, and distributed through non-regulated channels. A blend whose entire identity is an unsanctioned alias gets the honest visual home it deserves: a wall of tags *about* the claims, not a clinic façade and not a storefront.

The two spray colors carry the two peptides — a green BPC-157 tag, a blue TB-500 tag — the way the "synergy" claim overlaps two mechanisms. The red official-notice stencils and yellow caution flags carry the parts the marketing tends to leave off: no controlled combination study, no validated blend dose, Category 2 under FDA 503A, prohibited by WADA. The street claim, and the official line, on the same wall.

## How we handle the evidence

Three rules govern every page. First, the blend is read constituent by constituent — a finding from BPC-157 is tagged to BPC-157, a finding from TB-500 to TB-500, and a blend-level claim is flagged as having no combination data behind it. Second, every quantitative claim is tied to a cited study; if the literature does not establish something, the page says so rather than filling the gap. Third, the regulatory facts come only from authoritative sources, stated present-tense and never as predictions.

The result is a digest that celebrates what the constituent literature genuinely shows — the transected-tendon result, the VEGFR2 angiogenesis mechanism, the thymosin beta-4 actin-sequestration crystal structure — while refusing to dress up an extrapolation as a finding. Read [the cited studies and references](/references) to check any claim on the wall against its source.

---

A street-wall research digest on the BPC-157 TB-500 Wolverine blend — each peptide tagged to its own studies, every blend-level gap sprayed in plain sight beside the FDA 503A line, with no clinic behind the wall and nothing here to dispense.